Skip to content

Nektar Therapeutics NKTR FX Effect on Cash

FX Effect on Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$900K-250%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$122K+1,320%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$213K-142%
Incyte logo
IncyteINCY
-$2.69M-387%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$32K-178%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$25M-136%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's fx effect on cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's FX effect on cash?
Nektar Therapeutics (NKTR) reported FX effect on cash of $0 in Q1 2026.
How has Nektar Therapeutics's FX effect on cash changed year-over-year?
Nektar Therapeutics's FX effect on cash increased by 100.0% year-over-year, from -$1K to $0.
What does FX effect on cash mean?
The impact of exchange rate changes on the value of cash and equivalents held in foreign currencies.